FDA Announces Draft Guidance to Reduce vCJD Risk in Blood and Blood Products

Summary

The FDA is releasing a draft document that provides revised recommendations to reduce the risk of transmitting variant Creutzfeldt-Jakob Disease (vCJD) through blood and blood products, focusing on deferrals for individuals with a history of blood transfusion in Ireland from 1980 to the present.